Cap and Trade – A Horrible Idea – Let’s Abolish Cars and Build a Real Rail System Instead
May 13, 2009
Cap and Trade Is a very bad idea, right now.
First, a history lesson. President Clinton’s first term was a disaster, in large part, because he spent most of his first two years pursuing three very liberal ideas—gays in the military, universal health care, and a federal tax on BTU usage.
These three ideas were, at the time, in 1993-1995, so controversial, that they not only threatened to sink President Clinton after only one term, but resulted in 1994 in the largest shift in a mid-term election in the House of Representatives and the U.S. Senate in United States History.
The House lost more than fifty Democratic seats and went Republican for the first time in a long time; and the Senate also suffered huge democratic losses; all due to Newt Gingrich and the Contract with America, which was a direct and overwhelming refutation of Clinton’s liberal agenda.
Much the same thing happened in the first two years of Jimmy Carter’s term; Carter pardoned all of the draft-dodging Vietnam protesters hiding out in Canada, and virtually declared war on the CIA and all of the US military operations around the world, which led to terror operations and revolutions around the world intensifying, culminating in the Iranianian Revolution and the taking of the U.S. Embassy in Teheran and the holding of 52 U.S. hostages for over a year, a spectacle so embarassing to the United States, repeated night after night on national TV as it was, that virtually every Democrat in office lost his seat by 1980, and the Republicans and Ronald Reagan were swept into power, with a whole new agenda of re-arming America and restoring her lost prestige abroad.
Getting back to Clinton, the BTU Tax was an idea very similar to the current notion of Cap and Trade. Cap and Trade, like the BTU Tax, is essentially a tax on carbon usage. The idea is, if we tax carbon-based fossil fuels enough, and make them costly enough, it will force everyone, including consumers and energy companies, to seek non-carbon based alternatives.
There are three basic problems with cap and trade (actually, there are many more, but I will discuss three here) that make it a bad idea for now. First, we are in a recession that is actually more of a depression. Cap and Trade is a large TAX INCREASE that will suck spending power out of the hands of consumers. Consequently, it will kill the marginal propensity of consumer demand, and attack the very object of the Stimulus Bill.
I don’t have to be a doctor to know, that you don’t give a man a sleeping pill, just when you’ve given him a shot to wake him up, while he’s still groggy and coming around.
Right now, the American economy is like a man who can’t wake up. Cap and Trade would be like a sleeping pill to that man. The Stimulus Bill was like a cup of coffee or a shot of epinephrine—a stimulant to wake him.
Cap and Trade is like a sleeping pill that would suck away his vital energy.
Second, in order to invest in, and build, energy alternatives, there has to be a venture capital and investment banking, and regular banking systems, in place. Today, those systems are impaired, crippled or functioning at about half capacity. Consequently, Cap and Trade can’t work under today’s economic conditions. Consequently, no infrastructure would develop under Cap and Trade to produce renewable energy alternatives until the banking and lending systems come back on line.
All we’ll have is a tax that makes oil and gas and coal more expensive, but no alternatives will develop for many years yet, due to the impairments of the banking, VC and R & D systems.
Third, even if the banking, VC and R & D systems were perfect, there is no energy alternative that could come on line sooner than ten years from today to replace current oil, gas and coal based consumption.
Wind and solar currently provide less than 1% of current energy needs; energy needs keep GROWING at an exponential rate, if you include the third world, and none of the so-called renewable energy forms are anywhere close to being ready to assume more than a micro-share of the energy load, whether we’re talking about wind, solar, geothermal, capturing energy from ocean waves, and so forth.
It’s been fifty plus years since the hydrogen bomb, but no one has yet developed and sustained a fusion reaction that can last and power an energy generating plant. That technology seems as remote as the so-called “WARP” engines on the starship Enterprise on STAR TREK.
That leaves us with one, and only one realistic alternative, and that is nuclear power plants. They are tanned, rested and ready, and the newest generation of nukes have much higher capacity factors and higher safety factors than ever before.
The problem with nukes is, you still need about two billion dollars to build a single plant, about 3-4 years to get the necessary permits to build a plant in the U.S. and another 3-4 years to build the plant and get it on line.
That’s 6-8 years and two billion dollars to get each plant on line, and most of the two billion dollars will have to be absorbed by the consumer in electricity costs. Let’s figure that we build fifty of those plants—that’s a hundred billion dollars in construction costs alone that have to be absorbed back again by means of utility bills to the consumer over the next ten-twenty years. That’s on top of the cap and trade tax costs.
In short, it’s a very expensive proposition to jettison oil, gas and coal.
It’s too bad that the United States didn’t commit to a nukes policy back in 1955, when nuclear power was cheap and we could have covered the US with nuclear power plants for a fraction of the cost of today.
If we had committed to such a policy then, we could have been completely independent of Middle Eastern Oil as of 1970.
Even as late as 1975, we still could have committed to nukes for a fraction of today’s costs, and been independent of Middle Eastern Oil by the 1990s.
However, the wacky left and particularly eco-wacky californians, continuously opposed nuclear power in this country for decades. Nuclear power could have given us full independence from the Middle East a long, long time ago, and spared us these last two wars in Iraq and Kuwait.
The problems we face today are a consequence of our leaders living life as if we can’t shape the future. But we can and must shape the future.
The future is not shaped by dice rolling or by random events. The future is shaped by decisions we make and by policies we need to hew to in order to shape the probabilities and likelihoods of the future outcomes to be.
A responsible United States Government would have made us one hundred percent reliant on nuclear energy for our power production as soon as humanly possible, once we unlocked the secrets of the atom, back in the 1950s.
Our failures to do so may have been the result of many causes, and I won’t speculate here on the role of the oil and gas companies, the so-called, Seven Sisters, and their multinational interests linked to Middle Eastern oil producing states, but clearly nuclear energy would have a lot cheaper over the last sixty years than two wars fought directly by the US in the Middle East, and five wars fought by proxy between Israel and the oil-producing states.
Had we eliminated oil dependence early by committing to the atom, we would have changed history decisively and for the better.
Cap and Trade is not the answer.
A federally-sponsored program of accelerated conversion to Nuclear Powered electric generation, followed by a fifty to one hundred year phase in of solar, wind and fusion power, is the answer.
All electric companies should be abolished in favor of one company modeled and based on the Tennessee Valley Authority, that will erect Nukes until the United States is 100% nuclear based electric power, and zero percent coal or oil.
Combing this with a program of converting all cars to electric power would also solve another problem as well. This is clearly doable in the next five-ten years.
This is the kind of program that would involve spending money on a specific problem, creating jobs, and stimulating the economy. It’s better than cap and trade because it puts dollars into the economy instead of taking them out. Also, it federalizes the utilities, which do a horrible job.
Finally, the electric grid needs to be updated using superconductors and the latest electric technologies, including quantum conductors and new metals to conduct electricity. With superconductors, electricity can be sent from location to location without any loss of power or current. This would eliminate the need for transformers and high voltage lines, etc. Again, a vast federal program committed to upgrading the grid is needed.
These steps would be much better than cap and trade.
A final note about cars–Why do Obama and the Democrats want to prop up the car industry if they are truly worried about Global Warming? Cars contribute more than 50% of the hydrocarbon emissions in the US that contribute to global warming.
Instead of paying consumers a $4,000 tax credit to buy new cars with high gas mileage, wouldn’t it make more sense to get people to STOP DRIVING CARS AND TAKE MASS TRANSIT?
In short,
1) Let the U.S. Auto Industry DIE.
2) Put an enormous carbon tax on all car purchases. Make any new car cost around $50,000 to buy.
3) Apply that tax backwards to used cars as well.
4) Massively subsidize AMTRAK and all local mass transit across the nation, and let people ride the trains and Mass Transit free for the next five years. Yes, I said it, FREE OF CHARGE for the next five years. Why? To get them used to doing it. The massive federal stimulus bill to build rail, subway, light rail throughout the US would be in the TRILLIONS of dollars, as well as to subsidize AMTRAK everywhere so it’s FREE OF CHARGE. That would be a net STIMULUS to the economy and create the world’s finest light and heavy rail systems. We could also finally build HIGH SPEED RAIL SYSTEMS modeled on France, England and Japan to cover longer distances that could go 300-400 miles per hour, that could eliminate many shorter airplane routes, unclogging the skies of needless plane flight. This is a win, win, win plan. We get rid of filthy autos and planes and replace them with electric trains. And net net net create jobs.
5) Starting in 2014, you can slowly re-introduce fees again for Mass Transit and AMTRAK once we’ve started to eliminate all of the automobiles.
6) Start reclaiming the inner cities by closing roads and creating pedestrian zones and mass-transit zones, and creating more and more parks in which no cars can come into the city, until finally, all cities will have no cars or trucks at all.
7) The goal would be to eliminate cars and trucks by 2025, and convert everyone to mass transit and rail.
8) Electric cars only would be allowed eventually, powered by the nuclear grid. These would be cheap and affordable.
This is a far reaching and thoughtful plan. Abolish the internal combustion engine as we know it and force all americans out of their cars and onto trains, buses, subways and light rail.
This is the true path to ending global warming and reaching a green economy.
Art Kyriazis
Philly/South Jersey
Home of the World Champion Phillies
up
COMENT ON TIME’S COVER STORY ON STEM CELL RESEARCH OF FEBRUARY 9, 2009
February 10, 2009
Time Magazine just did a cover story on stem cell research, which is commendable. They also entitled the story “The Quest Resumes,” which is commendable, focusing on the fact that the Federal Government, under the Obama Administration, may finally allow (this may already have been approved by executive order) federal funds for stem-cell research at federally funded research institutions.
However, the subtitle of the article is “After eight years of political ostracism, stem-cell scientists like Harvard’s Douglas Melton are coming back into the light—and making discoveries that may soon bring lifesaving breakthroughs.” Time Feb 9, 2009 at p. 36.
Now, let’s examine that for a second—In Massachusetts, where Prof. Melton plies his craft, the Commonwealth and State of Massachusetts, like the State of California, has voted state support of stem-cell research at institutions of higher education. Therefore in Massachusetts, like California a bastion of biotechnology, the biotech lobby was able to secure state support for stem-cell research during the eight-year long federal ban on such research. So compared to the other 48 states, Prof. Melton was actually at an advantage because his lab was in Massachusetts.
Because of the federal funds ban, a great deal of stem cell-research has begun to spring up in places like Southeast Asia, as the Time Magazine article correctly notes, and as it well-known in the biotech industry. But a lot of it is also staying put in Cali and Mass due to those states putting up seed money for biotech research that is stem cell oriented.
Next, Prof. Melton works as co-director of the Harvard Stem Cell Institute (HSCI), which Harvard has committed substantial resources to supporting over the past eight years and well into the future. According to their 2008 report, their annual spending has grown in the past two years from just over $5 million to over $16 million in fiscal year 2008, most of that culled from private and corporate donations. HSCI currently has no less than eight ongoing challenge grant research projects sponsored for $75,000 each, all of them stem cell oriented.
Now I am a powerful supporter of stem-cell research, and I strongly advocate that the federal government support stem cell research. The question I have for Time Magazine is, and maybe perhaps for the Federal Government, is HSCI the most needy recipient for federal funds for stem cell research? The article omits that HSCI is well-funded by private donors, and omits that Massachusetts provides state support (it is not clear if HSCI accepts Massachusetts money) and therefore the article in Time is somewhat misleading.
The argument for funding HSCI federally has to be this; we, e.g. HSCI, made a good faith effort to get the ball rolling the past three years through private financing, we have already a lab in motion with research projects, so if you fund us, we will be three years closer to getting results than any other academic lab you choose to fun. Consequently, their NIH grant requests will carry a certain heft.
On the other hand, they are not as dramatically in need of the money as some other labs who don’t have any private funding at all.
A more useful article would have been to depict the overall situation in the rest of the United States, and some of the labs outside CA & MA.
This is an interesting issue and one on which arguments on both sides would and could be marshalled.
It should be pointed out that I strongly support the work of Prof. Melton and the work of HSCI. Those initiatives were put into place by then President Lawrence Summers, along with the Broad Institute initiative, a few years back, and clearly they have had the effect of putting Harvard back on the map in terms of genetics and molecular biology research.
The good news about the Time article is that the words “Stem Cells” made the cover, along with a nice bio-photo. If nothing else, Americans this week can forget about the economy and the war for a moment and realize that stem cell research is an answer to many of our problems that don’t involve boundaries and account balances and fumes spewing out of our cars.
–art kyriazis philly/south jersey
home of the world champion phillies
T-CELL SCIENCES, INC. – CASE STUDY – WHARTON SCHOOL CASE STUDY – 1994 – Arthur J. Kyriazis University of Pennsylvania April 22, 1994
January 26, 2009
this is an actual case study I did at Wharton about fifteen years ago for Steve Sammut’s class on advanced patent portfolio management theory. This case is of interest because it concerns a biotech company, and because, re-reading it after a long time, it actually reads very well. Even before I had all the experience I do now, I actually had a good feel for what to do with the management of a biotech company even back then, so here it is. And yes, I did get an “A” in the class, of course. Dr. Sammut used to run the tech transfer office for Penn during the 1990s.
–art k
ps enjoy!
T-CELL SCIENCES, INC. CASE
by Arthur J. Kyriazis
MGMT 898 – PROF. SAMMUT
Wharton School (WEMBA)
University of Pennsylvania
April 22, 1994
Issues
T-Cell Sciences, Inc. (“T-Cell”) is a 1983 Cambridge, MA biotech/pharmaceutical startup sired by Patrick Kung, a “recognized pioneer in immunological research.” The main issue appears to be defining T-Cell’s ultimate market niche even as it undergoes the process of transition from a venture-funded start-up to a more mature publicly held corporation. Specifically, in the coming months and years, should T-Cell (1) concentrate upon basic across the board immunological R&D; (2) concentrate upon basic immunological R&D with a focus on diagnostic drugs and product(s); or (3) focus upon strategic alliances with large pharmaceutical companies with an eye cast towards the development and delivery of therapeutic pharmaceutical drugs?
It would appear that until the arrival of James D. Grant as CEO in November of 1986, the main issue might well have been a different one altogether, namely whether T-Cell would reorganize or liquidate. In early 1986, T-Cell was a company in trouble and one which was not being particularly well-run or well-managed, even though it had brilliant scientists and innovative technologies full of commercial promise. Even though startups might be expected to lose money at the outset, T-Cell’s losses in 1985 and 1986 totalled nearly $2 million, compared with $5.5 million capitalization from December of 1983 throught January of 1986. This apparently necessitated a public offering in May of 1986, which raised $11.1 million, followed by the hiring of Mr. Grant in November of 1986, and his hiring of a well-heeled financial CFO immediately thereafter.
In addition, up through Grant’s arrival, T-Cell had only developed two products of any consequence, ACT-T-SET, and CELLFREE, and only two joint venture/research alliances/R&D contracts of any consequence, the Syntex USA contract and the Pfizer contract, and had failed to show any revenue from product sales through 1986, and only $13 million in revenue from contracts in 1986.
In brief, one may surmise from the case study that a great deal of money was spent at T-Cell, until Grant’s arrival, on basic immunological research, without a very well defined sense of where the research was going, or how it would be profitable or generate a return to the company and to the investors. This might have been a result of Dr. Kung’s diffuse vision of the company’s market niche as somehow doing R&D better or faster, and perhaps a touch of the academic fondness for the intrinsic value of broad based academic research as opposed to targeted research and strategic alliances directed to product development and ultimate profit.
Grant’s arrival placed T-Cell on a radically different footing and he appears to have turned the company around. Losses were reduced by nearly a million dolars from 1986 to 1987, and for the year ending in April of 1987, T-Cell reported positive product sales revenue of nearly $400,000 together with contract revenues of nearly $2 million. In addition, Grant apparently negotiated the deal with Yamanouchi Parmaceutical, which as he characterizes it places T-Cell on a sound cash flow footing for the foreseeable future. In addition, Grant has introduced a sound line of command and professionalized the management of the company by hiring a financial officer and a regulatory affairs officer, paying attention to patent management issues, and spending time painting a sound, attractive picture to shareholders, potential investors and to regulators. Finally, Grant’s status an a former FDA head bodes well for the regulatory hurdles awaiting T-Cell’s products.
T-Cell’s Strengths
T-Cell’s strengths are many. First, it has a distinguished corps of researchers led off by Dr. Kung, who appears to be a leader in the field of T cell research. It is situated in Cambridge, MA, in the heart of the Harvard-MIT research community, and can be expected to easily draw upon an outstanding technical scientific staff for its research needs. Also, the scientific advisory board includes people like Dr. Mark Davis and others who are world-recognized scientific leaders.
Second, T-Cell has introduced two product lines in 1986, the ACT-T-SET and CELLFREE technologies, which assuming patent protection and FDA approval, are potentially product mainstays for the company. These two products are expected to have applicability in the diagnosis of various stages of immune system stimulation and white blood cell activity. Dr. Kung and Mr. Grant expect R&D to eventually identify other new products in the same T cell related vein with applicability in the diagnostic field.
Third, T-Cell has two joint ventures, with Syntex and Pfizer, and now a third, with Yamanouchi, which promise to focus on specific product development, with the obvious potential of delivering a drug to market which can be of wide therapeutic applicability and therefore be a cash mainstay for the company. The Syntex and Pfizer ventures aim to produce therapeutic drugs targeted at common medical ailments, including breast cancer, type 1 diabetes, rheumatoid arthritis and cytomegalovirus. The Yamanouchi venture aims to develop products to diagnose rheumatoid arthritis and lung cancer. An added benefit is the global ability to develop and market products and drugs in Japan and the rest of the world while awaiting FDA approval for their sale in the United States.
Fourth, T-Cell now has James D. Grant, who must be reckoned as an important asset of the company at this juncture. His management skills have put T-Cell on a sound business footing; his contacts have resulted in new joint venture(s); and his FDA expertise should translate into FDA product approvals.
Which Fields or Options are Most Attractive for T-Cell?
The basic R&D approach is wrong for this size company. What the company needs to do is ultimately make a decision between developing diagnostic products/drugs on its own, or on developing them with partners. Grant appears to be committed to a strategy of hedging his bets by pursuing both options. He is willing to commit some money to R&D and to diagnostics, while courting and signing deals with large pharmaceuticals for strategic alliance(s) aimed at delivering specific types of therapeutic products/drugs. Grant also feels that the diagnostic(s) division, once profitable, should be spun off because of the competition in that field.
Recommendations
Grant probably has it right. The therapeutic emphasis is the best way for T-Cell to go right now. The joint venture/strategic alliance approach is a sound one. If successful, the development of even one drug marketed to a patient population as widespread as the breast cancer or lung cancer populations promises immediate payoff for T-Cell’s efforts and a handsome reward for its investors.
With diagnostic drugs on the other hand, even if approved and even if proprietary, it is hard to see how T-Cell will be able to exploit the discoveries, so that Grant is probably correct when he surmises that this division or these proprietary discoveries will ultimately be spun off. Of course, licensing and franchising are options we have discussed which absent from Grant’s discussion(s).
The best way for T-Cell to go would be to continue to solicity these contracts and joint ventures. T-Cell has recognized, proven scientific talent and recognized expertise in this very specific area of immunological research.
One specific recommendation is that the company hire a patent portfolio manager and begin to concentrate on patenting more of its discoveries, as well as concentrate on getting products to FDA submission stage. This manager must also concentrate on getting the researchers to recognize when a discovery may or might be patentable or commerciable in some respect. These two steps will make the company attractive to investors and a steady stream of patent application(s) and FDA approval applications are evidence that a company has been doing its homework.
These steps, if followed, should result in a successful new round of equity financing and/or an invitation to buy the company out altogether. In either event, the company will have attained a substantial goal. Finally, T-Cell should keep Grant around. Given the company’s history, investors could get extremely nervous if he were to depart suddenly or unexpectedly.
–Arthur J Kyriazis, 1994
THIS WAS AN ACTUAL CASE STUDY I WROTE FOR THE WHARTON SCHOOL IN THE SPRING OF 1994.
–art kyriazis
Philly/South Jersey
Home of the World Champion Philadelphia Phillies
Home of the Incredible Philadelphia Eagles
Home of the Arena Football League Champion Philadelphia Soul
Making the Playoffs in 2008: The Sixers, the Flyers, the Phillies and the Eagles!
Happy New Year 2009

